

GI Division Research/Grand Rounds Conference

GI Division Research/Grand Rounds Conference - 6/20/2023 School of Medicine - Main Campus June 20, 2023 – 7:30 AM

Learning Objectives

Upon completion of this session, learners should be able to:

- 1 Learn the techniques to improve the number of people being screened for colon cancer and the skills to improve the quality of screening.
- 2 Optimized treatment of hepatitis C. Treatment of Hepatitis C has improved dramatically in the last couple of years yet there is a gap in terms of optimal drug treatment for effective eradication of hepatitis C.
- 3 Inflammatory bowel disease management is changing with increased use of biological agents. Practitioners need to understand when these are most cost efficient to use for IBD patients.
- 4 Achalasia treatment has evolved. Participants should be able to identify achalasia patients and streamline pre, peri, & post treatment outcomes.

Target Audience

Specialties – Gastroenterology/Hepatology, Internal Medicine Professions – Physician, Nurse, Other, Physician Assistant, Scientist / Researcher

Accreditation

The University of California San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of California San Diego School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit*(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*™ from organizations accredited by ACCME or a recognized state medical society.

Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts *AMA PRA Category 1 Credits*™ issued by organizations accredited by the ACCME. For relicensure, the California Board of Registered Nursing accepts *AMA PRA Category 1 Credits*™.

Disclosure Statement

All relevant financial relationships and the nature of those relationships are noted below. All relevant financial relationships have been mitigated.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Joshua Rubin, MD	Co-Director	Nothing to disclose - 03/02/2023
Syed Fehmi, MD, Professor	l(Tourse I)irector	Consulting Fee-Boston Scientific Corporation - 03/02/2023

Laurel Branch, MD	Faculty	Nothing to disclose - 02/23/2023
Mark Kowalczyk, MD	Faculty	Nothing to disclose - 05/11/2023
Selena Kuo, MD	Faculty	Nothing to disclose - 02/22/2023
Priya Sharma, MD	Faculty	Nothing to disclose - 11/09/2022
Erin Song, MD	Faculty	Nothing to disclose - 02/28/2023
Erin Wolf, MD	Faculty	Nothing to disclose - 03/29/2023
Maryam Zafer, MD, MPH	Faculty	Nothing to disclose - 05/18/2023

Acknowledgment of Commercial Support
This session has received no commercial support.